| Species |
Human |
| Protein Construction |
B2M/beta 2-Microglobulin (Ile21-Met119)
Accession # P61769-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
38.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
To assess whether beta-2 microglobulin (B2M) has effects on articular chondrocytes that would implicate B2M involvement in osteoarthritis (OA) pathogenesis.The average B2M level in OA synovial fluid is significantly higher than that found in normal synovial fluid. B2M is highly expressed in OA cartilage and synovial fluid compared to normal, and suggest that B2M may have effects on chondrocyte function that could contribute to OA pathogenesis. |
| Synonyms |
Beta-2-microglobulin;B2M;β-2-microglobulin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
